Trial Profile
PEAX: Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge), Abiraterone Acetate (Zytiga) or Enzalutamide (Xtandi) Undergoing Cardiopulmonary EXercise Testing
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Mar 2019
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary) ; Enzalutamide (Primary) ; Sipuleucel-T
- Indications Adenocarcinoma; Prostate cancer
- Focus Pharmacodynamics
- Acronyms PEAX
- 16 Feb 2019 Results (n=28) presented at the 2019 Genitourinary Cancers Symposium.
- 06 Feb 2019 Status changed from active, no longer recruiting to completed.
- 20 Sep 2018 Status changed from recruiting to active, no longer recruiting.